Conv. Plasma
Nigella Sativa

All regdanvimab studies
Meta analysis
study COVID-19 treatment researchRegdanvimabRegdanvimab (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Ventilation -151% Improvement Relative Risk Oxygen therapy 54% Hospitalization 49% Composite outcome 49% Recovery time 35% Time to viral- 2% Regdanvimab  Streinu-Cercel et al.  EARLY TREATMENT  DB RCT Is early treatment with regdanvimab beneficial for COVID-19? Double-blind RCT 307 patients in multiple countries Faster recovery (p<0.0001) and viral clearance (p=0.041) Streinu-Cercel et al., Open Forum Infe.., Feb 2022 Favors regdanvimab Favors control

Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients with Mild-to-Moderate Coronavirus Disease 2019

Streinu-Cercel et al., Open Forum Infectious Diseases, doi:10.1093/ofid/ofac053, NCT04602000
Feb 2022  
  Source   PDF   All   Meta
35th treatment shown to reduce risk in March 2022
*, now known with p = 0.0000009 from 7 studies, recognized in 27 countries. Efficacy is variant dependent.
Lower risk for hospitalization, progression, and recovery.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments.
Phase 2 RCT with 307 outpatients with mild-moderate COVID-19, showing regdanvimab (monoclonal antibody) resulted in a minor decrease in time to negative PCR test (primary endpoint) compared to placebo, which was not statistically significant. Regdanvimab did significantly reduce time to clinical recovery by 3 days compared to placebo. A composite outcome of requiring hospitalization or oxygen therapy occurred in 4.4% of regdanvimab patients versus 8.7% placebo, with greater differences in moderate disease patients (7.2% vs 15.8% placebo). No safety issues were identified.
Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for omicron BA.2, BA.4, BA.5 Haars, ХВВ.1.9.1, XBB.1.9.3, XBB.1.5.24, XBB.1.16, XBB.2.9, BQ.1.1.45, CL.1, and CH.1.1 Pochtovyi.
risk of mechanical ventilation, 151.2% higher, RR 2.51, p = 1.00, treatment 1 of 203 (0.5%), control 0 of 104 (0.0%), continuity correction due to zero event (with reciprocal of the contrasting arm).
risk of oxygen therapy, 54.5% lower, RR 0.46, p = 0.11, treatment 8 of 203 (3.9%), control 9 of 104 (8.7%), NNT 21.
risk of hospitalization, 48.8% lower, RR 0.51, p = 0.20, treatment 9 of 203 (4.4%), control 9 of 104 (8.7%), NNT 24.
composite outcome, 48.8% lower, RR 0.51, p = 0.20, treatment 9 of 203 (4.4%), control 9 of 104 (8.7%), NNT 24.
recovery time, 35.2% lower, relative time 0.65, p < 0.001, treatment mean 5.7 (±0.408) n=203, control mean 8.8 (±1.22) n=104.
time to viral-, 1.6% lower, relative time 0.98, p = 0.04, treatment mean 12.7 (±0.969) n=203, control mean 12.9 (±0.306) n=104.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Streinu-Cercel et al., 2 Feb 2022, Double Blind Randomized Controlled Trial, placebo-controlled, multiple countries, peer-reviewed, 17 authors, trial NCT04602000 (history). Contact:
This PaperRegdanvimabAll
Efficacy and Safety of Regdanvimab (CT-P59): A Phase 2/3 Randomized, Double-Blind, Placebo-Controlled Trial in Outpatients With Mild-to-Moderate Coronavirus Disease 2019
Anca Streinu-Cercel, Oana Săndulescu, Liliana-Lucia Preotescu, Jin Yong Kim, Yeon-Sook Kim, Shinhye Cheon, Young Rock Jang, Sang Joon Lee, Sung Hyun Kim, Ilsung Chang, Jee Hye Suh, Seul Gi Lee, Mi Rim Kim, Da Rae Chung, Han Na Kim, Adrian Streinu-Cercel, MD Joong Sik Eom
Open Forum Infectious Diseases, doi:10.1093/ofid/ofac053
Background. Regdanvimab (CT-P59) is a monoclonal antibody with neutralizing activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report on part 1 of a 2-part randomized, placebo-controlled, double-blind study for patients with mild-to-moderate coronavirus disease 2019 . Methods. Outpatients with mild-to-moderate COVID-19 received a single dose of regdanvimab 40 mg/kg (n = 100), regdanvimab 80 mg/kg (n = 103), or placebo (n = 104). The primary end points were time to negative conversion of SARS-CoV-2 from nasopharyngeal swab based on quantitative reverse transcription polymerase chain reaction (RT-qPCR) up to day 28 and time to clinical recovery up to day 14. Secondary end points included the proportion of patients requiring hospitalization, oxygen therapy, or mortality due to COVID-19. Results. Median (95% CI) time to negative conversion of RT-qPCR was 12.8 (9.0-12.9) days with regdanvimab 40 mg/kg, 11.9 (8.9-12.9) days with regdanvimab 80 mg/kg, and 12.9 (12.7-13.9) days with placebo. Median (95% CI) time to clinical recovery was 5.3 (4.0-6.8) days with regdanvimab 40 mg/kg, 6.2 (5.5-7.9) days with regdanvimab 80 mg/kg, and 8.8 (6.8-11.6) days with placebo. The proportion (95% CI) of patients requiring hospitalization or oxygen therapy was lower with regdanvimab 40 mg/kg (4.0% [1.6%-9.8%]) and regdanvimab 80 mg/kg (4.9% [2.1%-10.9%]) vs placebo (8.7% [4.6%-15.6%]). No serious treatment-emergent adverse events or deaths occurred. Conclusions. Regdanvimab showed a trend toward a minor decrease in time to negative conversion of RT-qPCR results compared with placebo and reduced the need for hospitalization and oxygen therapy in patients with mild-to-moderate COVID-19. Clinical trial registration. NCT04602000 and EudraCT 2020-003369-20.
Supplementary Data Supplementary materials are available at Open Forum Infectious Diseases online. Consisting of data provided by the authors to benefit the reader, the posted materials are not copyedited and are the sole responsibility of the authors, so questions or comments should be addressed to the corresponding author.
Baden, Sahly, Essink, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine, N Engl J Med
Barek, Aziz, Islam, Impact of age, sex, comorbidities and clinical symptoms on the severity of COVID-19 cases: a meta-analysis with 55 studies and 10014 cases, Heliyon
Blanco-Melo, Nilsson-Payant, Liu, Imbalanced host response to SARS-CoV-2 drives development of COVID-19, Cell
Brookmeyer, Crowley, A confidence interval for the median survival time, Biometrics
Chen, Nirula, Heller, SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med
Clinicaltrials, A study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in preventing SARS-CoV-2 infection and COVID-19 in nursing home residents and staff (BLAZE-2) (NCT04497987)
Gisaid, Tracking of variants: VOC Delta, relative variant genome frequency per region
Gottlieb, Nirula, Chen, Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell
Kim, Jang, Hong, Safety, virologic efficacy, and pharmacokinetics of CT-P59, a monoclonal antibody against SARS-CoV-2 spike receptor binding protein: two randomised phase 1 studies in healthy subjects and patients with mild SARS-CoV-2 infection, Clin Ther
Kim, Ryu, Lee, A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein, Nat Commun
Lilly, Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
Liu, Wang, Nair, Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike, Nature
Perkin, Heap, Crerar-Gilbert, Deaths in people from Black, Asian and minority ethnic communities from both COVID-19 and non-COVID causes in the first weeks of the pandemic in London: a hospital case note review, BMJ Open
Polack, Thomas, Kitchin, Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine, N Engl J Med
Sadoff, Gray, Vandebosch, Safety and efficacy of single-dose Ad26. COV2.S vaccine against Covid-19, N Engl J Med
Shi, Shan, Duan, A human neutralizing antibody targets the receptorbinding site of SARS-CoV-2, Nature
Stephenson, Gars, Sadoff, Immunogenicity of the Ad26.COV2.S vaccine for COVID-19, JAMA
Weinreich, Sivapalasingam, Norton, REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19, N Engl J Med
Wiley, Kubes, Cobb, Age, comorbid conditions, and racial disparities in COVID-19 outcomes, J Racial Ethn Health Disparities
Wilson, Probable inference, the law of succession, and statistical inference, J Am Stat Assoc
Wu, Wang, Shen, A noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2, Science
Zost, Gilchuk, Case, Potently neutralizing and protective human antibodies against SARS-CoV-2, Nature
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop